Analysts predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post earnings of ($0.17) per share for the current quarter, according to Zacks. Three analysts have made estimates for Halozyme Therapeutics’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.22). Halozyme Therapeutics reported earnings per share of ($0.16) during the same quarter last year, which suggests a negative year over year growth rate of 6.3%. The company is expected to issue its next quarterly earnings report after the market closes on Tuesday, August 6th.

On average, analysts expect that Halozyme Therapeutics will report full-year earnings of ($0.42) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.36). For the next financial year, analysts expect that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.87) to ($0.23). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. The business had revenue of $56.95 million during the quarter, compared to analysts’ expectations of $67.80 million. During the same period in the prior year, the company earned ($0.19) earnings per share. The business’s revenue was up 84.3% compared to the same quarter last year.

A number of brokerages have recently commented on HALO. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. Cantor Fitzgerald began coverage on shares of Veru in a report on Monday, July 1st. They issued an “overweight” rating and a $6.00 target price for the company. ValuEngine raised shares of Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Finally, Zacks Investment Research cut shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Halozyme Therapeutics has an average rating of “Hold” and a consensus price target of $21.00.

Shares of NASDAQ:HALO traded up $0.17 on Monday, reaching $16.96. The company’s stock had a trading volume of 489,625 shares, compared to its average volume of 806,147. The business has a 50-day moving average price of $16.63. Halozyme Therapeutics has a 52-week low of $13.24 and a 52-week high of $18.85. The company has a quick ratio of 2.72, a current ratio of 2.95 and a debt-to-equity ratio of 0.07. The company has a market cap of $2.44 billion, a PE ratio of -30.29 and a beta of 1.77.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Trust Advisors LP grew its holdings in Halozyme Therapeutics by 128.5% during the 4th quarter. First Trust Advisors LP now owns 82,339 shares of the biopharmaceutical company’s stock valued at $1,205,000 after purchasing an additional 46,301 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at $157,000. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 36.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,097,080 shares of the biopharmaceutical company’s stock valued at $16,050,000 after purchasing an additional 294,909 shares in the last quarter. Geode Capital Management LLC grew its holdings in Halozyme Therapeutics by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 1,520,657 shares of the biopharmaceutical company’s stock valued at $22,247,000 after purchasing an additional 76,753 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its holdings in Halozyme Therapeutics by 8.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 402,884 shares of the biopharmaceutical company’s stock valued at $5,894,000 after purchasing an additional 32,721 shares in the last quarter. 82.08% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Recommended Story: What is meant by buying and selling pressure?

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.